Skip to content

Continuous And Data-drivEN CarE (CADENCE) Pilot

Continuous And Data-drivEN CarE (CADENCE)

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05609669
Acronym
CADENCE
Enrollment
10
Registered
2022-11-08
Start date
2023-08-23
Completion date
2027-09-30
Last updated
2025-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use Disorder, Pregnancy Related

Brief summary

The proposed project seeks to use public health and clinical data on opioid use disorders (OUD) outcomes for mother and infants, which is the leading cause of death to mothers one year after deliver and can lead to neonatal withdrawal syndrome (NOWS) and other poor outcomes. Insufficient or incomplete data about OUD and lack of integrated programs for OUD treatment during pregnancy can be barriers to providing optimal care to mothers and infants.

Detailed description

Maternal opioid use disorder (OUD) is the leading cause of maternal mortality in the first year after delivery nationwide. OUD also contributes substantially to out-of-home placements in the child welfare system. Medication for OUD (MOUD) is the primary standard of treatment, however, access to MOUD and prenatal care is limited, siloed, and fragmented in Florida. Gaps in access to and continuity of healthcare (prenatal, postpartum, pediatric, pharmacological and behavioral health) and other services for mothers in OUD recovery lead to poor outcomes for parent, child and family. There is also insufficient data integration, due to inconsistent data collection methods or use of diagnostic codes, to identify mother-infant dyads affected by OUD that could inform optimal care at the local level. Single-site studies that integrate substance use disorder programs in pregnancy have been shown to improve neonatal and maternal outcomes. With that in mind, the long-term goal of this study is to leverage high-quality local and timely data to improve OUD outcomes before, during, and after pregnancy with an integrated care approach that can be replicated throughout the state. The objective of the proposed project is to consolidate multiple streams of public health and clinical healthcare data to analyze equitable access and outcomes for families affected by maternal OUD for use in quality improvement cycles to rapidly refine our integrated CADENCE (Continuous and Data-Driven Care) Program. Our central hypothesis is that integrated, continuous, data-driven care will improve CADENCE patient outcomes. We will test this hypothesis through the following aims: 1) create an interactive data dashboard for maternal, neonatal, and infant outcomes for pregnancies affected by OUD; 2) pilot the CADENCE program and rapidly refine using a data-driven approach.

Interventions

OTHERCADENCE program

The CADENCE program will consist of an integrated care pathway between the OBOT clinic, obstetric clinic, pediatric clinic, and behavioral health with multiple entry points, including emergency rooms, existing mobile harm reduction clinics, obstetric clinics, and delivery facilities. We also seek to provide wrap-around care for these families with peer support, care navigation, and robust community support, using existing Hillsborough County resources such as doula programs, Healthy Start, and other home visiting programs.

Sponsors

University of South Florida
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with known opioid use disorder over the age of 18 years old who are pregnant

Exclusion criteria

* Patients without opioid use disorder, less than 18 years old, incarcerated, or non-pregnant

Design outcomes

Primary

MeasureTime frameDescription
MOUD at delivery hospitalizationAt delivery hospitalizationPatients on subutex or methadone treatment at delivery hospitalization (yes/no)
Decreased pharmacologically treated NOWSAt deliveryMedication clinically required for NOWS (yes/no)

Secondary

MeasureTime frameDescription
Prenatal care adequacyPrenatal care, up to 40 weeksKotelchuck index (score)
Hepatitis C screeningPrenatal care, up to 40 weeksHepatitis C antibody screen collected during prenatal care (yes/no)
NICU admissionsAt delivery hospitalizationAdmission to the NICU during delivery admission for any reason (yes/no)
First trimester entry to prenatal carePrenatal care, up to 40 weeksFirst prenatal care visit before 14 weeks gestational age (yes/no)
Department of Children and Families out-of-home placementAt delivery hospitalizationNeonate placed in care of another family or with a foster family who is not the biological parents. This does not include planned adoptions. (yes/no)
Breastfeeding at dischargeAt delivery hospitalizationExclusive breastfeeding at discharge from delivery admission (yes/no)
Enrollment in community supports and services.Prenatal up to 1 year oldProportion of referrals to connection/enrollment in services (%)
Hospital length of stay (neonate)At delivery hospitalizationNumber of days in hospital during delivery admission (#)

Other

MeasureTime frameDescription
Acceptability of CADENCE ProgramPrenatal up to 1 year oldPatient satisfaction gauged by qualitative interview and quantitative surveys
Trialability of CADENCE ProgramPrenatal up to 1 year oldAbility to integrate into clinical flow as gauged by Clinical staff qualitative interview and quantitative surveys
Feasibility of CADENCE ProgramPrenatal up to 1 year oldNumber of patients recruited per month, number of patients enrolled in program

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 10, 2026